Open AccessThis article is
- freely available
Anticoagulation in the Elderly
Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital and Faculty of Medicine, 4 rue Gabrielle Perret-Gentil CH-1211 Geneva 14, Switzerland
* Author to whom correspondence should be addressed.
Received: 7 October 2010; in revised form: 7 December 2010 / Accepted: 9 December 2010 / Published: 10 December 2010
Abstract: Management of anticoagulation in elderly patients represents a particularly challenging issue. Indeed, this patient population is at high thromboembolic risk, but also at high hemorrhagic risk. Assessment of the benefit-risk balance of anticoagulation is the key point when decisions are made about introducing and/or continuing such treatments in the individual elderly patient. In order to maximise the safety of anticoagulation in the elderly, some specific considerations need to be taken into account, including renal insufficiency, modified pharmacodynamics of anticoagulants, especially vitamin K antagonists, and the presence of multiple comorbidities and concomitant medications. New anticoagulants could greatly simplify and possibly increase the safety of anticoagulation in the elderly in the near future.
Keywords: anticoagulation; elderly patient; vitamin K antagonist; hemorrhagic risk; factor-Xa inhibitor; thrombin inhibitors
Citations to this Article
Cite This Article
MDPI and ACS Style
Robert-Ebadi, H.; Righini, M. Anticoagulation in the Elderly. Pharmaceuticals 2010, 3, 3543-3569.
Robert-Ebadi H, Righini M. Anticoagulation in the Elderly. Pharmaceuticals. 2010; 3(12):3543-3569.
Robert-Ebadi, Helia; Righini, Marc. 2010. "Anticoagulation in the Elderly." Pharmaceuticals 3, no. 12: 3543-3569.